Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study.
Szaflik
Jacek P
JP
Szaflik
Jerzy
J
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D018450:Disease Progression; D006801:Humans; D007267:Injections / Q000379:methods*; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology; D018918:Phacoemulsification; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014786:Vision Disorders / Q000209:etiology / Q000517:prevention & control*; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab